tbuckley/cabot-search huggingface dataset:
Abstract 13501: Measures of Three-dimensional Left Ventricular Mechanics Deteriorate Acutely After Cardiotoxic Cancer Therapy
Authors: Kathleen W Zhang, Benjamin French, Gaurav Gulati, Hari K Narayan, Akinyemi Bajulaiye, Carina Zhang, David Hyman, Bonnie Ky
Journal: Circulation (2015)

Background: Doxorubicin and trastuzumab are commonly used breast cancer therapies with established cardiotoxic effects. However, the changes in myocardial mechanics with cancer therapy cardiotoxicity remain poorly defined, and noninvasive measures are needed to identify patients at increased risk. Our objective was to define the acute changes in three-dimensional (3D) echocardiography-derived indices of cardiac mechanics in patients receiving these therapies. Methods: In a prospective, longitudinal cohort of women with breast cancer receiving doxorubicin and/or trastuzumab, we obtained 3D echocardiography images before therapy (baseline) and during therapy at 3 months and 1 year of follow-up. Images were acquired at a minimum of 22 frames per second and analyzed by two readers using a vendor-independent analysis platform (TomTec Cardiac Performance Analyses, Unterschleissheim, Germany). Left ventricular twist, torsion, and principal strain were quantitated semi-automatically using 3D speckle tracking imaging. Standard descriptive statistics were used to summarize these measures over time. Results: Eighty-seven patients (mean age at baseline 49 years, 65% Caucasian) contributed at least 1 observation to the analysis. At baseline, median twist was 10.96° (interquartile range [IQR] 6.64, 13.59), torsion was 1.41°/cm (IQR 0.86, 1.70), and principal strain was -30.40% (-33.64, -28.55). At 3 months and 1 year, there were consistent declines in twist, torsion, and principal strain as displayed in Table I. Conclusions: In a prospective cohort of women with breast cancer receiving doxorubicin and/or trastuzumab, left ventricular twist, torsion, and principal strain declined over the first year of therapy. Ongoing research is focused on determining the clinical significance of these changes over time. Table 1. Longitudinal changes in 3D twist, torsion, and principal strain; summaries presented as median (interquartile range).
Methodology Flaws and Implications of a Complementary Medicine Study
Authors: Linda E. Carlson, Ting Bao, Lynda G. Balneaves
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Time-dependent biases in observational studies of comparative effectiveness research in rheumatology. A methodological review
Authors: Michele Iudici, Raphaël Porcher, Carolina Riveros, Philippe Ravaud
Journal: Annals of the Rheumatic Diseases (2019)

To assess to what extent time-dependent biases (ie, immortal time bias (ITB) and time-lag bias (TLB)) occur in the latest rheumatology observational studies, describe their main mechanisms and increase the awareness on this topic.We searched PubMed for observational studies on rheumatic diseases published in leading medical journals in the last 5 years. Only studies with a time-to-event analysis exploring the association of one or more interventional strategies with an outcome were included. Each study was labelled as free from bias, at risk of TLB, at risk of misclassified ITB if the period of immortal time was incorrectly attributed to an intervention group, or at risk of excluded ITB if the immortal time was discarded from the analysis.We included 78 papers. Most studies were performed in Europe or North America (46% each), were not industry funded (62%) and had a safety primary outcome (59%). In total, 13 (17%) studies were considered at risk of time-dependent biases. Among the studies at risk of ITB (n=8; 10%), in 5 (6%), waiting time to receive treatment was wrongly attributed to the treatment exposure group, which indicated misclassified ITB. Five (6%) studies were at risk of TLB: patients on conventional synthetic disease-modifying antirheumatic drugs (DMARD; first-line drugs) were compared with patients on biologic DMARDs (second or third-line drugs) without accounting for disease duration or prior medication use.One in six comparative effectiveness observational studies published in leading rheumatology journals is potentially flawed by time-dependent biases.
Biliary tract cancers and the associated risk of venous thromboembolism.
Authors: Jasleen Khanuja, Samira Bahrami Tabar, Denice Tsao-Wei, Caroline Irene Piatek, Afsaneh Barzi
Journal: Journal of Clinical Oncology (2019)

304 Background: Venous thromboembolism (VTE) is a common cause of morbidity and mortality in cancer patients. Because biliary tract cancers (BTC) cholangiocarcinoma and gallbladder (GB) cancer are uncommon, the incidence of VTE in this population are not well-described. Methods: We conducted a retrospective study of patients with BTC identified by the cancer registry at the Los Angeles County-University of Southern California (USC) Medical Center, USC Norris Cancer Center, and USC Keck Hospital between January 2011 to December 2016 to describe the incidence of VTE. 330 BTC patients’ medical records were reviewed for demographics, tumor characteristics, treatment history, and VTE events. 41 patients were excluded due to incomplete records/follow-up. Overall survival (OS) was calculated from date of diagnosis to date of death or last follow-up. Logrank test was used to evaluate the association of VTE with OS. Results: 289 patients with BTC were identified (177 cholangiocarcinoma, 112 GB) with a median follow-up period of 16.7 (0.3-89.0) months (mo). 169 (58%) were women. The median age at diagnosis of 66 years (range 22-89). 144 (59%) underwent cancer surgery and 274 (95%) received chemotherapy. 65 (22%) patients had VTE events: 22 pulmonary embolism [PE] with or without lower extremity (LE) deep vein thrombosis [DVT], 15 with LE DVT alone, three with upper extremity DVT, and 30 with visceral thrombosis (27 portal vein thrombosis [PVT] with or without inferior vena cava thrombosis [IVC], 2 IVC thrombosis, two hepatic vein thrombosis). Five patients had both DVT/PE and visceral thrombosis. The median time from cancer diagnosis to VTE event was not met. Patients with a PVT or any visceral thrombosis had an inferior OS compared to those without (PVT: median OS 16.2 mo [95% CI 12.2-25.8] versus 7.5 [3.4-14.2], p = 0.10, visceral thrombosis: 17.0 mo [95% CI 11.8-25.9] versus 8.4 [95% CI 3.7-14.3], p = 0.30). There was a non-significant trend towards inferior OS in patients with any VTE event type (median OS 17.0 mo [95% CI 11.8-39.0] versus 11.4 [95% CI 7.2-18.4], p = 0.10). There was no difference in OS for patients with PE/DVT compared to those without. Conclusions: VTE is commonly observed in patients with BTC. Visceral thrombosis is associated with inferior survival in patients with BTC.
Abstract 13547: Predictors of Obstructive Coronary Artery Disease in Adults With Cardiac Arrest
Authors: Jignesh K Patel, Ganesh Thippeswamy, Charles Loeb, Puja Parikh
Journal: Circulation (2017)

Introduction: Coronary angiography is a key component of systematic, multi-disciplinary post-cardiac arrest (CA) care, however, coronary angiogram is not routinely performed in the setting of CA. H...
Enterovirus D68–Associated Acute Flaccid Myelitis
Authors: Kevin Messacar, Kenneth L. Tyler
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm
Authors: Sho Kubota, Kenji Tokunaga, Tomohiro Umezu, Takako Yokomizo, Motohiko Oshima, Eisaku Iwanaga, Norio Asou, Atsushi Iwama, Kazuma Ohyashiki, Motomi Osato, Goro Sashida
Journal: Blood (2018)
Abstract 15090: Circulating miR-503 and miR-374b-5p are associated With Heart Failure
Authors: Lee Lee Wong, Eng Leng Saw, Shera Lilyanna, Eliana C Martinez, Carolyn S.P. Lam, Arthur M Richards
Journal: Circulation (2015)

Introduction: Circulating microRNA (miRNAs) profiles are dysregulated in heart failure (HF) suggesting possible diagnostic and prognostic applications. In addition, miRNAs may yield insights into the pathophysiology of HF and provide targets for therapeutic intervention. We sought to identify miRNAs diagnostic utility in HF and to further investigate selected miRNAs as potential targets for therapeutic intervention. Hypothesis: We hypothesized that distinct circulating miRNAs are dysregulated in HF and may be potentially important targets of therapy to improve outcomes for HF. Methods: Plasma miRNAs levels were profiled from 338 well-characterized HF patients and 208 age-matched controls without HF. We also examined selected miRNAs expression in a rat post-myocardial infarction (MI) model. Target predictive databases were used to identify potential miRNA targets. Results: Comparison between HF and non-HF controls was carried out by multivariate analysis. Seventy five miRNAs differed significantly between HF and non-HF controls after adjustment for age, hypertension, diabetes and atrial fibrillation (p-value after FDR&lt;0.01). Twenty four miRNAs with AUC&gt;0.65 , p&lt;0.001 (for discrimination of HF from non-HF controls on receiver-operator analysis) were highly up- or down-regulated significantly in clinical data comparing HF vs non-HF controls and were further examined in plasma samples from a rat post-MI model. Results showed that levels of miR-503 (AUC=0.73, FC (Fold Change) =1.69, p&lt;0.001) was higher and of miR-374b-5p (AUC=0.71, FC=-1.45, p&lt;0.001) lower when comparing HF patients with non-HF controls. In rat experimental model, levels of miR-503 (FC=2.21, p=0.017) increased and of miR-374b-5p (FC=-1.35, p=0.02) decreased after post-MI at Day 2 and Day 7, but not significant in Day 14 comparing with sham. MiR-503 has been reported to target CCNE1 and cdc25A. The predicted target for miR-374b is NPPB . The roles of miR-503 and miR-374b-5p in HF warrant further investigation using both in-vitro and in-vivo preclinical HF models. Conclusion: We provide a detailed study of circulating miRNA profiling in both clinical HF and experimental model. We demonstrated that circulating miR-503 and miR-374b-5p are associated with HF.
Characterization of subjects experiencing selective hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs)
Authors: Natalia Pérez-Sánchez, Inmaculada Doña, Maria Salas, Testera-Montes Almudena, Francisca Gomez, Maria Auxiliadora Guerrero, M.D. Cañamero, Cristobalina Mayorga, Jose A. Cornejo-Garcia, M.J. Torres
Journal: Journal of Allergy and Clinical Immunology (2019)
Abstract B66: P53 expression and survivin subcellular localization contribute to the diagnosis and prognosis of patients with astrocytomas
Authors: Roberta Soares Faccion, Paula Sabbo Bernardo, Giselle Pinto de Faria Lopes, Leonardo Soares Bastos, Cristina Lordello Teixeira, José Antonio de Oliveira, Priscila Valverde Fernades, Luiz Gustavo Dubois, Leila Maria Chimelli, Raquel Ciuvalschi Maia
Journal: Clinical Cancer Research (2018)

Abstract Astrocytomas are the most frequent subtype of primary central nervous system (CNS) tumors. Diffuse astrocytoma (grade II), anaplastic astrocytoma (grade III) and glioblastoma (GB–grade IV) are diffuse infiltrating astrocytomas derived from glial cells or precursors. Despite continuous efforts from the scientific community, these tumors still have a poor prognosis. Histologic grading is still challenging, and prognostic factors are still limited to age and tumor grade. Biomarkers that could improve histologic grading, especially that could help differentiate grade III from the other subtypes, and/or serve as prognostic factors are much needed. Furthermore, the relationship between survivin and p53 in astrocytoma progression and survival is still controversial. The present study aims to investigate the role of these proteins in the accuracy of histologic grading of diffuse astrocytic tumors and treatment response. One hundred thirty-five formalin-fixed, paraffin-embedded astrocytoma samples were obtained from patients. Tumor samples were reviewed and stained for survivin and p53 by immunohistochemistry, and the staining levels and survivin subcellular localization were correlated with histologic grading and patient outcomes. Age and histologic grade were the only clinical features that had a prognostic impact. High nuclear survivin and p53 correlated with grade III astrocytomas. High cytoplasmic survivin correlated with GB. Furthermore, patients whose tumors expressed high cytoplasmic survivin, high nuclear surviving, or high p53 and did not receive radiotherapy had worse short-term and long-term survival. Our results suggest that survivin subcellular localization and p53 expression improve the accuracy of histologic grading. Patients whose tumors overexpress these proteins benefit from radiotherapy regardless of age and histologic grade. Furthermore, patients whose tumors overexpress survivin may benefit from novel targeted antisurvivin treatment. Citation Format: Roberta Soares Faccion*, Paula Sabbo Bernardo*, Giselle Pinto de Faria Lopes*, Leonardo Soares Bastos, Cristina Lordello Teixeira, José Antonio de Oliveira, Priscila Valverde Fernades, Luiz Gustavo Dubois, Leila Maria Chimelli, Raquel Ciuvalschi Maia. P53 expression and survivin subcellular localization contribute to the diagnosis and prognosis of patients with astrocytomas [abstract]. In: Proceedings of the AACR International Conference held in cooperation with the Latin American Cooperative Oncology Group (LACOG) on Translational Cancer Medicine; May 4-6, 2017; São Paulo, Brazil. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(1_Suppl):Abstract nr B66.
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Authors: Ingrid A. Mayer, Aleix Prat, Daniel Egle, Sibel Blau, J. Alejandro Pérez Fidalgo, Michael Gnant, Peter A. Fasching, Marco Colleoni, Antonio C. Wolff, Eric P. Winer, Christian F. Singer, Sara Hurvitz, Laura García Estévez, Peter A. van Dam, Sherko Kümmel, Christoph Mundhenke, Frankie Holmes, Naveen Babbar, Laure Charbonnier, Ivan Diaz-Padilla, Florian D. Vogl, Dalila Sellami, Carlos L. Arteaga
Journal: Clinical Cancer Research (2019)

Addition of alpelisib to fulvestrant significantly extended progression-free survival in PIK3CA-mutant, hormone receptor-positive (HR+) advanced/metastatic breast cancer in the phase III SOLAR-1 study. The combination of alpelisib and letrozole also had promising activity in phase I studies of HR+ advanced/metastatic breast cancer. NEO-ORB aimed to determine whether addition of alpelisib to letrozole could increase response rates in the neoadjuvant setting.Patients and Methods: Postmenopausal women with HR+, human epidermal growth factor receptor 2-negative, T1c-T3 breast cancer were assigned to the PIK3CA-wild-type or PIK3CA-mutant cohort according to their tumor PIK3CA status, and randomized (1:1) to 2.5 mg/day letrozole with 300 mg/day alpelisib or placebo for 24 weeks. Primary endpoints were objective response rate (ORR) and pathologic complete response (pCR) rate for both PIK3CA cohorts.In total, 257 patients were assigned to letrozole plus alpelisib (131 patients) or placebo (126 patients). Grade ≥3 adverse events (≥5% of patients) in the alpelisib arm were hyperglycemia (27%), rash (12%), and maculo-papular rash (8%). The primary objective was not met; ORR in the alpelisib versus placebo arm was 43% versus 45% and 63% versus 61% in the PIK3CA-mutant and wild-type cohorts, respectively. pCR rates were low in all groups. Decreases in Ki-67 were similar across treatment arms and cohorts. In PIK3CA-mutant tumors, alpelisib plus letrozole treatment induced a greater decrease in phosphorylated AKT versus placebo plus letrozole.In contrast to initial results in advanced/metastatic disease, addition of alpelisib to 24-week neoadjuvant letrozole treatment did not improve response in patients with HR+ early breast cancer.
Deleterious alterations in DNA-damage repair (daDDR) genes as a predictive biomarker for platinum-based chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
Authors: Sofia Palacio, Hannah Stowe McMurry, Robert Ali, Talia Donenberg, Rachel Silva-Smith, Gina Wideroff, Daniel A. Sussman, Caio Max Sao Pedro Rocha Lima, Peter Joel Hosein
Journal: Journal of Clinical Oncology (2019)

266 Background: Germline genetic testing and somatic genomic profiling using commercial multigene panels are now routine in mPDAC. A subset of these patients have deleterious alterations in genes involved with DDR. Herein we investigate the role of daDDR as a predictive biomarker for response to first-line platinum-based chemotherapy. Methods: Utilizing the IRB-approved pancreas cancer and genetics clinic databases at the University of Miami, we identified all patients with mPDAC who had germline and/or somatic mutation testing. We performed a retrospective chart review to extract demographic and clinical characteristics including treatments received, response and survival. Results: Between 2012 and 2018, 116 patients with mPDAC underwent germline (using Invitae, Ambry Counsyl or Myriad) and/or somatic testing (using FoundationOne CDx). Among these, 40 received first-line therapy with FOLFIRINOX (95%) or gemcitabine/cisplatin (5%). The median age was 59 years and 15 (38%) were female. The majority (70%) were Hispanic and 63% had de-novo mPDAC (treatment-naïve). Germline testing revealed daDDR in 5 patients and somatic NGS found an additional 4 patients with daDDR (total of 9 (23%), including 5 with BRCA2, one each with BRCA1, RAD51C, ATM and MUTYH). The median progression-free survival (PFS) was significantly longer in patients with daDDR than without (17.3 vs 7.8 months, log-rank p = 0.01). The median overall survival (OS) was not statistically different between the two groups. Three patients with daDDR had complete or near-complete radiological and tumor marker responses to FOLFIRINOX and were treated with olaparib (a PARP inhibitor) as maintenance and remain progression-free after 7, 12.4 and 13.6 months respectively. Conclusions: daDDR appears to define a subset of patients with mPDAC who may be more sensitive to platinum agents. There are currently no biomarkers for selection of first-line therapy in patients with mPDAC and we demonstrate that this composite biomarker which is easily done via commercially available assays may be able to inform treatment selection.
Results of Autologous and Allogeneic Transplantation in Patients with Primary Plasma Cell Leukemia: A Large Retrospective Analysis of the Chronic Malignancies Working Party of the EBMT
Authors: Sarah Lawless, Simona Iacobelli, Nina Knelange, Patrice Chevallier, Didier Blaise, Noel-Jean Milpied, Robin Foà, Jan J Cornelissen, Bruno Lioure, Victoria Potter, Xavier Poire, Eefke J. Petersen, Matthew P. Collin, Stig Lenhoff, John Snowden, Stella Santarone, Keith Wilson, Jose E. Guimaraes, Peter Dreger, Martin R. Schipperus, Curly Morris, Stefan Schönland, Ibrahim Yakoub-Agha, Laurent Garderet, Kroger Nicolaus
Journal: Blood (2018)
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis
Authors: Zobair M. Younossi, Maria Stepanova, Quentin M. Anstee, Eric J. Lawitz, Vincent Wai-Sun Wong, Manuel Romero-Gomez, Kathryn Kersey, Georgia Li, G. Mani Subramanian, Robert P. Myers, C. Stephen Djedjos, Takeshi Okanoue, Michael Trauner, Zachary Goodman, Stephen A. Harrison
Journal: Clinical Gastroenterology and Hepatology (2019)
Reducing maternal deaths from hypertensive disorders: learning from confidential inquiries
Authors: Frances Conti-Ramsden, Marian Knight, Marcus Green, Andrew H Shennan, Lucy C Chappell
Journal: BMJ (2019)

<b>Lucy Chappell and colleagues</b> examine the dramatic reduction in maternal deaths from hypertensive disorders of pregnancy in the UK and discuss how systematic confidential inquiries may have contributed
Questioning Lay Health Worker Influence on Goals-of-Care Documentation and Patient Satisfaction—In Reply
Authors: Manali I. Patel
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)
Authors: Catherine Cordonnier, Sigrun Einarsdottir, Simone Cesaro, Roberta Di Blasi, Malgorzata Mikulska, Christina Rieger, Hugues de Lavallade, Giuseppe Gallo, Thomas Lehrnbecher, Dan Engelhard, Per Ljungman
Journal: The Lancet Infectious Diseases (2019)